ASIC Launches Formal Investigation Into KPMG Australia Partners Over Client Data Misuse Allegations 
Switch Eyes Multi-Billion-Dollar Funding Round at $50 Billion Valuation Ahead of Potential IPO 
MOL Gets More Time to Negotiate Acquisition of Russian-Owned Stake in Serbia’s NIS 
SpaceX Sets IPO Price at $135 Per Share Ahead of Historic Nasdaq Debut 
DeepSeek Targets $7.4 Billion Funding Round, Valuation Could Reach $59 Billion in 2026 
South Korea Weighs AI Profit Sharing as Samsung and SK Hynix Earnings Surge 
Quantinuum Raises $1.68 Billion in Upsized Nasdaq IPO Amid Growing Quantum Computing Demand 
Alaska Air Group Eyes Return of Financial Guidance as Fuel Market Volatility Eases 
Foreign Firms Cash In on India's IPO Boom 
Atlas Renewable Energy Freezes $1 Billion Brazil Investment Amid Renewable Energy Curtailment 
US Expands Iran Sanctions, Targets Major Crypto Exchanges and Individuals 
Bouygues, Orange and Iliad Strike €20.35 Billion Deal to Acquire SFR 
Lululemon Cuts 2026 Outlook as Weak North America Sales Pressure Growth 
CrowdStrike Beats Q1 FY2027 Expectations, Raises Outlook Despite After-Hours Stock Decline 
Jensen Huang Strengthens Nvidia’s South Korea Ties Amid AI Expansion 
TSMC Sees Strong AI-Driven Growth as Demand for Advanced Chips Continues to Surge 
Netflix Names Jay Hoag as Board Chairman Following Reed Hastings’ Departure 
SAN DIEGO, Nov. 08, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
